FLONASE SENSIMIST OTC
Generic Name and Formulations:
Fluticasone furoate 27.5mcg; per nasal spray; scent- and alcohol-free.
Indications for FLONASE SENSIMIST:
Relieves symptoms of hay fever or other upper respiratory allergies. Ocular symptom relief (in patients ≥12yrs).
Initially 2 sprays in each nostril once daily for Week 1, then 1 or 2 sprays in each nostril once daily as needed for Week 2 through 6 months. Reevaluate after 6 months.
<2yrs: not recommended. Use for the shortest duration necessary to achieve response. ≥2–11yrs: 1 spray in each nostril once daily. Reevaluate after 2 months.
Not for treating asthma. Injury or surgery to nose that is not fully healed: not recommended. Discontinue if exposed to chicken pox, measles, or tuberculosis. Glaucoma. Cataracts. Discontinue if whistling sound from nose, visual disturbances, severe or frequent nosebleeds occur. Discontinue if no improvement within 7 days after starting or if new symptoms (eg, facial pain, nasal discharge) develop. Avoid eyes or mouth. Pregnancy. Nursing mothers.
Caution with concomitant ritonavir, ketoconazole, other steroids.
Stinging, sneezing, headaches, dry/irritated nose or throat, nosebleeds, whistling sound, blurred or reduced vision, reduced growth rate in children, allergic reaction (discontinue if occurs).
Spray—9.9mL (60 sprays); 15.8mL (120 sprays)
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|